Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy

QR Code

Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy

Kristen Ward,1 Leslie Citrome2 1Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI, USA; 2Department of Psychiatry and Behavioral Science, New York Medical College, Valhalla, NY, USA Abstract: The purpose of this review is to describe the available data for...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Ward K, Citrome L
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2019
Sujets:	akathisia weight gain second-generation antipsychotics atypical antipsychotics relapse-prevention Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Accès en ligne:	https://doaj.org/article/5c1b5039e9ed40a3af76e91e8bf985ed
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Post hoc analyses of asenapine treatment in pediatric patients with bipolar I disorder: efficacy related to mixed or manic episode, stage of illness, and body weight
par: Findling RL, et autres
Publié: (2018)

Atypical antipsychotics as add-on treatment in late-life depression
par: Cakir S, et autres
Publié: (2016)

Taiwan Expert Consensus Recommendations for Switching to Aripiprazole Long-Acting Once-Monthly in Patients with Schizophrenia
par: Chih-Sung Liang, et autres
Publié: (2021)

An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder
par: Citrome L, et autres
Publié: (2021)

An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder [Corrigendum]
par: Citrome L, et autres
Publié: (2021)

The Relationship between the Second-Generation Antipsychotics Efficacy and the Traditional Chinese Medicine Body Constitutions in Patients with Schizophrenia
par: Tzu-Pei Yeh, et autres
Publié: (2021)

A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future
par: Citrome L, et autres
Publié: (2019)

Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
par: Montemagni C, et autres
Publié: (2016)

Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a real-world clinical setting
par: Di Lorenzo R, et autres
Publié: (2019)

Case Report: Cariprazine Efficacy in Young Patients Diagnosed With Schizophrenia With Predominantly Negative Symptoms
par: Octavian Vasiliu
Publié: (2021)

Gabapentin enacarbil for antipsychotic induced akathisia in schizophrenia patients: a pilot open-labeled study
par: Takeshima M, et autres
Publié: (2018)

Electroconvulsive Therapy as a Corrector for Certain Side Effects of Antipsychotic Therapy
par: Yu. V. Bykov, et autres
Publié: (2020)

Lack of tolerable treatment options for patients with schizophrenia
par: Citrome L, et autres
Publié: (2015)

Antipsychotic-associated weight gain: management strategies and impact on treatment adherence
par: Dayabandara M, et autres
Publié: (2017)

The Relationship Between Antipsychotic-Induced Akathisia and Suicidal Behaviour: A Systematic Review
par: Kalniunas A, et autres
Publié: (2021)

Association between IL-6 and metabolic syndrome in schizophrenia patients treated with second-generation antipsychotics
par: Fang X, et autres
Publié: (2019)

Use of atypical antipsychotics in the elderly: a clinical review
par: Gareri P, et autres
Publié: (2014)

The modern perspective for long-acting injectables antipsychotics in the patient-centered care of schizophrenia
par: Pietrini F, et autres
Publié: (2019)

Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies
par: Barabássy Á, et autres
Publié: (2021)

Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies [Corrigendum]
par: Barabássy Á, et autres
Publié: (2021)

COMPARISON OF TWO WIDELY USED ATYPICAL ANTIPSYCHOTICS OLANZAPINE VERSUS RISPERIDONE IN TERMS OF METABOLIC OUTCOMES
par: Shiraz Hussain, et autres
Publié: (2021)

Examining the safety, efficacy, and patient acceptability of inhaled loxapine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults
par: Faden J, et autres
Publié: (2019)

Cariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy
par: Citrome L
Publié: (2018)

A Random Forest Model for Predicting Social Functional Improvement in Chinese Patients with Schizophrenia After 3 Months of Atypical Antipsychotic Monopharmacy: A Cohort Study
par: Li Y, et autres
Publié: (2021)

Priapismo secundario a antipsicóticos: a propósito de un caso asociado a risperidona
par: Cruzado,Lizardo, et autres
Publié: (2012)

Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: post hoc analyses of three placebo-controlled studies
par: Thase ME, et autres
Publié: (2018)

Metabolic disturbances in patients with paranoid schizophrenia treated with atypical antipsychotic drugs
par: Leonid Mikhaylovich Bardenshteyn, et autres
Publié: (2010)

Antipsychotic medication-mediated cognitive change in schizophrenia and polygenic score for cognitive ability
par: Rachael K. Blackman, et autres
Publié: (2022)

The More, the Merrier…? Antipsychotic Polypharmacy Treatment Strategies in Schizophrenia From a Pharmacology Perspective
par: Stephan Hjorth, et autres
Publié: (2021)

Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia
par: Brasso C, et autres
Publié: (2017)

Changes in Brain Structure, Function, and Network Properties in Patients With First-Episode Schizophrenia Treated With Antipsychotics
par: Ping Yin, et autres
Publié: (2021)

Pharmacological Treatment of Bipolar Depression: What are the Current and Emerging Options?
par: Yalin N, et autres
Publié: (2020)

Effects of Lithium Combined with Second-Generation Antipsychotics for the Treatment of Manic Episodes in Patients with Bipolar Disorder: A Naturalistic Study in China
par: Liu Y, et autres
Publié: (2020)

Treatment Goals in Schizophrenia: A Real-World Survey of Patients, Psychiatrists, and Caregivers in the United States, with an Analysis of Current Treatment (Long-Acting Injectable vs Oral Antipsychotics) and Goal Selection
par: Fitzgerald HM, et autres
Publié: (2021)

Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review
par: Emsley R, et autres
Publié: (2018)

Diabetes mellitus inducida por olanzapina: Caso clínico
par: Rojas G,Paula, et autres
Publié: (2001)

Esquizofrenia y su asociación con enfermedades médicas crónicas
par: Orellana,Gricel, et autres
Publié: (2017)

Targets, attitudes, and goals of psychiatrists treating patients with schizophrenia: key outcome drivers, role of quality of life, and place of long-acting antipsychotics
par: de Bartolomeis A, et autres
Publié: (2016)

Diagnosis and Treatment of Depression in Patients with Schizophrenia
par: Sergey N. Mosolov
Publié: (2020)

Determinants Of Antipsychotic Drugs Prescription Among Community-Living Older Adults With Dementia: A Population-Based Study Using Health Information Systems In The Lazio Region, Italy
par: Bargagli AM, et autres
Publié: (2019)